Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03179995 · ClinicalTrials.gov registry record · Phase 2
Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03179995 is a Phase 2 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 23 participants.
The verdict
NCT03179995, a Phase 2 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This will be a prospective, randomized, double blind trial enrolling patients who will undergo major liver resection. Patients will be randomized in a 1:1 ratio to receive either octreotide or placebo in the postoperative period. The patients will receive octreotide intravenously continuously for five days after operation. During this period the patients' health will be monitored by performing blood tests including complete metabolic profile, Complete Blood Count (CBC) with/diff., INR and PTT. The functioning of heart will also be monitored post-operatively by EKG. Up to 80 participants will be accrued over a 2 year period. Volumetric CT scans will be performed prior to hepatectomy, 1 week after hepatectomy and 3 months after hepatectomy to evaluate liver regeneration.
Interventions
- OTHER Placebo
- DRUG Octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-07-07 |
| Est. Completion | 2020-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03179995
The ClinicalTrials.gov registry entry for NCT03179995 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03179995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03179995 about?
NCT03179995 is a clinical study titled "Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy". This will be a prospective, randomized, double blind trial enrolling patients who will undergo major liver resection. Patients will be randomized in a 1:1 ratio to receive either octreotide or placebo in the postoperative period. The patients will receive octreotide intravenously continuously for fi...
What is the current status of trial NCT03179995?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2017-07-07. Estimated completion is 2020-02-12.
What interventions are being tested in trial NCT03179995?
The interventions under investigation include: Placebo (OTHER), Octreotide (DRUG).
Who is sponsoring clinical trial NCT03179995?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.